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Several strategies aim at characterizing the AIDS epidemic in different parts of the world.
Among these, the identification of recent HIV-1 infections using the recently described serologic
testing algorithm for recent human immunodeficiency virus (HIV) seroconversion (STARHS)
strategy was employed in four testing sites of the City of São Paulo Public Health Department
(CSPPHD). Those identified as recently infected were invited to participate in a prospective
clinical and laboratory evaluation study. We describe the establishment of the patient identification
network and the success in enrolling the participants, as well as their clinical and laboratory
characteristics. From May to December 2002, 6,443 persons were tested for HIV in the four
participating sites, of whom 384 (5.96%) tested HIV-1 positive; 43 (11.2%) of them were identified
as recently infected. Twenty-two were successfully enrolled in the follow-up study, but three of
them did not meet clinical and/or laboratory criteria for recent HIV-1 infection. After these
exclusions, the laboratory findings revealed a median CD4+ T lymphocyte count of 585 cells/µL
(inter-quartile range 25-75% [IQR], 372-754), a CD8+ T lymphocyte count of 886 cells/µL (IQR,
553-1098), a viral load of 11,000 HIV-RNA copies/mL (IQR, 3,650-78,150), log10 of 4.04 (IQR
3.56-4.88). The identification of recent HIV infections is an extremely valuable way to evaluate the
spread of the virus in a given population, especially when cohort studies, considered the gold
standard method to evaluate incidence, are not available. This work demonstrated that establishing
a network to identify such patients is a feasible task, even considering the difficulties in a large,
resource-limited country or city.
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The identification of individuals recently infected
with human immunodeficiency virus (HIV) is an
important tool to address the transmission dynamics
and to establish a target population to develop
virology and immunology studies. Recently, a new
approach was developed to help identify such
subjects, utilizing the Serologic Testing Algorithm for
Recent HIV Seroconversion (recently termed
STARHS) strategy, which combines the use of a
sensitive enzyme immunoassay (EIA) with a
modified, less sensitive (LS) version of EIA,
originally using the 3a11 reagents kit (Abbott
Laboratories, Abbott Park, IL, USA) [1], but also
validated with the HIV-1 Microelisa System
(BioMerieux, Raleigh, NC, USA) [2].
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STARHS is based on the slow increase in antibodies
observed during the early period of infection, then
reaching a plateau [3-6]. In the STARHS method, a
standard commercial diagnostic EIA is modified to
reduce its sensitivity to a point where serum samples
with low antibody titers are weakly reactive or negative
in the LS assay. A blood specimen that is reactive on a
sensitive EIA but non-reactive on the LS EIA identifies
a person in the early period of HIV infection. The time
between seroconversion on the sensitive EIA and the LS
EIA has been estimated to be 170 days (95% confidence
interval: 145-200 days) for HIV-1 subtype B [7].
Identifying recent infection subjects and samples
enables epidemiological studies [8-13],
characterization of the clinical and laboratory
presentation, identification of the circulating viral strains
[9, 14], and the constitution of a sample repository
for immunological and viral evolution studies.
We developed a network involving the Federal
University of Sao Paulo (UNIFESP) and the City of
São Paulo Public Health Department (CSPPHD) to
identify subjects recently infected by HIV-1, using the
STARHS strategy, aiming at enrolling these individuals
for prospective follow-up. We examined the
establishment of the network and the success in enrolling
the patients, as well as their clinical and laboratory
characteristics.
Material and Methods
Network establishment
The CSPPHD is the largest network providing care
for HIV-infected patients in the São Paulo metropolitan
area. Twenty-three clinical sites provide health care to
infected patients throughout the city, including eight
dedicated to offering HIV testing and counseling
centers.
Four of these services were selected for this study:
Henfil and Campos Elíseos, both located in the central
area of the city, Lapa, located in the north, and Pirituba,
located in the west. Data collection took place from
May to December 2002, but the sites began the
collection at different time points, from May to July. At
all four sites, persons presenting for HIV testing were
informed about the study and then about a new HIV
testing technology was used to identify recent infection.
A signed informed consent was obtained from all who
agreed to the STARHS testing procedure in addition
to the HIV testing offered by the testing site.
The subjects were asked to return to the testing site
10 to 14 days after giving a blood sample, for access
to the results and post counseling. The flow of activities
is depicted in the Figure 1 algorithm.
Serological tests
Blood was collected in vacuum tubes, allowed to
clot, and transported on the same day to the central
laboratory of the CSPPHD. Two enzyme immunoassays
(EIA) were run. Samples with two non-reacting EIA
results were considered negative. Those with
indeterminate or reacting results in one or two EIA assays
were submitted to a confirmatory Western-Blot assay.
If the result was indeterminate or positive, the
volunteer was asked to donate a second sample for
HIV testing, in accordance with Brazilian Ministry of
Health Guidelines [15].
Any sample with a positive result obtained at the
central laboratory of the CSPPHD was flagged and an
aliquot was transported to the Retrovirology
Laboratory at the Federal University of Sao Paulo.
These samples were again analyzed using the STARHS.
Briefly, the samples were re-tested using the
Vironostika HIV-1 Microelisa System (BioMerieux,
Raleigh, NC, USA) EIA, which employs testing of a
1:20,000 dilution of the specimen under modified
incubation conditions. The Vironostika negative control,
CDC calibrator, CDC high positive control and CDC
low positive control were all diluted and incubated in
the same manner as the specimens described above.
Samples were initially screened (one well per sample)
and all the controls were run in triplicate. The sample
optical density (OD) value was standardized as follows:
SOD = sample OD – average negative control OD ÷
average CAL OD – average negative control OD.
Samples with screening SOD below 2.0 were re-
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tested in triplicate in a confirmatory test. The SOD was
calculated using the median OD of the triplicates. A
sample with SOD below 1.0 in the confirmatory mode
was classified as an infection probably acquired in the
last 170 days. The result of STARHS was transmitted
to the four sites within 10 days after the blood was
drawn.
Since the sample could be submitted to a STARHS
assay if it were positive at the first round of testing, all
the volunteers were informed about the test and were
offered the opportunity to sign an informed consent
authorizing it, if the standard immunoenzymatic assay
resulted positive.
Volunteer enrollment
At the returning visit of any subject after the first
blood was drawn, the test result and counseling were
offered at the four testing sites. If the subject tested
positive for HIV antibodies, a second blood sample
was taken to confirm the first result, again in accordance
with Brazilian Ministry of Health Guidelines.
If a seropositive subject was identified as recently
infected according to the STARHS assay, the volunteer
was offered the option to participate in a protocol
involving prospective clinical visits and blood collection
at the Outpatient Clinic of the Federal University of
Sao Paulo. If the volunteer accepted, a second
informed consent was explained and offered, allowing
participation in the protocol. A rapid HIV antibody test
and a hematocrit were performed using a fingertip
puncture. Females were also asked for a urine sample
for a dipstick pregnancy test. Volunteers younger than
18 years old, with a negative rapid test, a hematocrit
below 28%, or who were pregnant, were not enrolled
in the study. The subjects were then submitted to the
second blood drawn for further tests, and were asked
to come to a scheduled visit at the Federal University
of Sao Paulo within 15 days. Samples were submitted
to CD4+ T lymphocyte counts, and plasma viral load
determination.
All the data was stored in a spreadsheet, organized
in a data bank and afterwards analyzed using Statistica
software, version 6.0 (Statsoft, Inc., Tulsa, OK, USA).
Results
Identification of recently infected cases
From May to December 2002, 6,443 persons were
tested for HIV in the four participating sites, of whom
384 (5.96%) tested positive for HIV antibodies. Figure
2 describes the number of tests and distribution in the
four sites. Among the 384 patients who tested positive
for HIV antibodies, 43 (11.2%) were identified as
recently infected using the STARHS testing strategy:
25 were from Henfil, 14 from Campos Elíseos, three
from Lapa, and one from Pirituba, corresponding to
58.1%, 32.6%, 7.0%, and 2.3% of the new diagnosed
HIV-infections, respectively. The highest percentage
of recently infected HIV subjects was 15.8% at Lapa,
followed by 13.9% at Henfil, 8.3% at Campos Elíseos,
and 5.9% at Pirituba.
Upon identification of a potential recently infected
HIV-1 subject, the individual was invited to participate
in the follow-up study at the Federal University of São
Paulo outpatient clinic. The accumulated number of
patients identified and enrolled in this protocol during
the study period is depicted in Figure 3.
Enrollment and clinical and laboratory characteristics
findings
All the HIV-infected patients with a negative
STARHS assay result who came back to know their
HIV serostatus were asked to participate in a protocol
at UNIFESP, involving prospective clinical exams and
laboratory follow-up. Twenty-two patients decided to
participate and they were enrolled in the protocol by
the end of December 2002, corresponding to 51% of
identified cases. Most of the enrollees were identified
at Henfil, followed by Campos Eliseos, Lapa, and
Pirituba (Figure 3). The average time between the first
visit at the service and the subsequent visit for other
laboratory tests was 19 days (range, 3-50 days).
The demographical, epidemiological, clinical and
laboratory characteristics of the enrolled patients are
described in Table 1. Three patients (13%) did not
meet the criteria for a recent HIV infection. The first
Detection of Recent HIV Infection in São Paulo
www.bjid.com.br
402 BJID 2004; 8 (December)
0 20 40 60 80 100 120 140 160 180 200
Henfil
Cam pos E liseos
Lapa
Pirituba
Num ber of tests
Negative  at STARHS
Positive at STARHS
5.9%
15.8%
8.3%
13.9%
Counseling and informed consent authorizing the STARHS test
HIV antibody testing at the Lapa Central Laboratory
HIV-positive HIV-negative
Post counseling
STARHS test at UNIFESP
Positive (no recent infection) Negative (recent infection)
Visit for testing at the counseling and testing site
Post counseling and 
referral to an HIV clinic
Signature of the informed 
consent for enrollment into
the follow-up study
Study first visit and blood collection at UNIFESP
Figure 1. Algorithm for identification and enrollment of recently-infected HIV subjects. The first visit took place
at one of the four sites: Henfil, Campos Eliseos, Lapa, and Pirituba. HIV-positive samples were transported to the
Federal University of São Paulo (UNIFESP) for STAHRS. Those patients identified as a potential recent HIV-
1 infection were invited to provide a sample and were referred to the UNIFESP outpatient clinic.
Figure 2. Number of HIV-positive tests at the four testing centers from May to December 2002 and respective
STARHS results. The percentage of samples suggesting recent HIV-1 infection at each site is indicated.
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(patient 2001) tested negative for HIV antibodies at
the second blood test, with normal values of CD4+ and
CD8+ T lymphocyte counts, and an undetectable viral
load; he was then considered uninfected and the first
test was considered a false positive. Two other patients
(patients 1014 and 2007) had a clinical history and
CD4+ T lymphocyte counts that suggested established,
chronic infection.
Two patients (10%) had symptoms within the past
four months compatible with primary HIV infection
within the six months prior to enrollment, according to
a physician’s judgment. The first (1002) had fever,
muscle pain, lymph node enlargement, and oral lesions
lasting for five days, followed by spontaneous
resolution. The second (1011) reported fever for 20
days, also resolving spontaneously.
After excluding the three patients who did not meet
clinical and laboratory criteria for recent infection, the
laboratory findings revealed a median CD4+ T
lymphocyte count of 585 cells/µL (inter-quartile range
25%-75% [IQR], 372-754), a CD8+ T lymphocyte
count of 886 cells/µL (IQR, 553-1098), and a viral
load of 11,000 HIV-RNA copies/mL (IQR, 3,650-
78,150), log10 of 4.04 (IQR 3.56-4.88).
Two patients presented with low CD4+ counts.
Patient 2006 had a history of a negative test for HIV
antibodies one year before, and a CD4+ T lymphocyte
count of 215 cells/µL, but follow-up evaluations
demonstrated increasing numbers (236 and 320 cells/
µL, at 31 and 60 days, respectively, after the first
follow-up study visit). Patient 1015 reported a highly
suspicious contact before the first HIV antibody testing.
However, no symptoms compatible with primary
infection were reported. The first CD4+ count revealed
146 cells/mL, followed by 121 cells/mL 36 days after,
which motivated the initiation of antiretroviral therapy.
Figure 3. Dynamics of identification (open circles) and enrollment of recent HIV-infected patients (closed circles).
The bars represent the number of enrolled patients at each site by month.
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Table 1. Characteristics of the patients enrolled in the follow-up study
Age Time History CD4+ T CD8+ T HIV-RNA
Patient ID (years) Gender between of symptoms cells/µL cells/µL (copies/mL)
1001 34 M 6 MSM No 372 491 59,300
1002 38 M 4 MSM Yes 619 ,952 14,300
2001 27 M 36 Hetero - 661 471 ,<80
2002 21 M 41 Hetero No 558 886 16,000
1004 34 F 14 Hetero No 489 ,987 97,000
2003 70 M 50 Bisex No 969 559 11,000
1005 24 M 29 MSM No 424 547 ,340
1006 24 F 7 Hetero No 362 443 1,900
1007 37 M 13 MSM No 788 1,147 1,000
1008 34 M 7 Hetero No 349 570 4,400
1009 25 M 42 MSM No 837 1,636 49,000
2004 36 M 21 Bisex No 709 116 6,800
2005 27 M 22 Bisex No 726 894 3,500
1010 38 M 3 MSM No 1,442 877 3,800
1011 27 M 15 MSM Yes 698 4,680 178,000
1012 28 M 27 MSM No 910 633 6,330
2006 69 M 8 Hetero No 215 329 248,000
1013 19 M 14 MSM No 585 1,772 2,870
1014 40 M 22 Hetero No 21 444 >750,000
1015 23 M 11 MSM No 146 1,532 428,000
1016 23 M 11 MSM No 372 1,049 426,000
2007 34 F 18 Hetero No 10 144 34,600
* - MSM: men who have sex with men; Hetero: heterosexual; Bisex: bisexual.
** - NA: Not available.
Discussion
The identification of recent HIV infections is an
extremely valuable way to evaluate the spread of the virus
in a given population, especially when cohort studies,
considered the gold standard method to evaluate incidence,
are not available. Among the several observations, one
could address important issues, such as the estimation of
incidence rate, the characterization of the high-risk
population, the profile of circulating viruses, and the
identification of primary resistance to antiretroviral
agents in patients recently infected by HIV-1.
We describe a successful collaborative work to
identify recently-infected HIV-1 patients in the São
Paulo metropolitan area, a region recognized as the
Brazilian AIDS epidemic epicenter as a consequence
of the high proportion (22%) of the AIDS cases
reported to the Brazilian Ministry of Health [16].
Therefore, the identification of such patients will
contribute to a better understanding of HIV-1 epidemic
characteristics and dynamics in this area. It is necessary,
however, to exert caution due to the potential inclusion
of patients with very advanced disease, who can
resemble recently infected subjects according to
Detection of Recent HIV Infection in São Paulo
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STARHS. Hence, it is always advisable to obtain
clinical and laboratory information to consider a recent
infection case, using the proposed algorithm.
Patient laboratory findings were compatible with
recently infected patients, who presented with high
median CD4+ T lymphocyte counts (585 cells/µL) and
low viral loads (11,000 HIV-RNA copies/mL). These
results are in accordance with the findings of Fiebig et
al. [17], who classified HIV-1 acute and recent infection
in plasma donors in six distinct stages. Using the
proposed criteria, patients identified with STARHS are
classified as stage V or VI, in whom the median viral
loads were 18,700 and 12,150 HIV-RNA copies/mL,
respectively, similar to what was found in our study.
One of the major characteristics of the targeted
patient population is that the majority is constituted of
men who have sex with men (MSM). This could be
explained by the special attention that the four
participating sites have concentrated on the MSM
population. In the city of São Paulo, MSM account
for approximately one third of the overall reported
AIDS cases, and this type of sexual activity is the main
transmission route in the population served by the
participating sites in this study [18]. New strategies have
been designed and implemented to target other
populations, including heterosexuals and intravenous
drug users, considering their role in the city of São Paulo
epidemic.
Recent HIV Infection Study Group Participants
(by institution)
Federal University of São Paulo – Ana Carolina
Denadai Sanchez, Celso Francisco Hernandez
Granato, Gilberto Turcato, Helena Tomiyama, Marli
Fátima de Oliveira Campos, Milena Karina Coló
Brunialti, Graziela Tescarollo, Reinaldo Salomão and
Ricardo Sobhie Diaz; City of São Paulo Public Health
Department Central Office – Deolinda Parra and Maria
Amélia Mascena Veras; Henfil Counseling Testing
Center – Carmela Zacaro and Elizete Aparecida dos
Santos; Specialized Attending Service in DST/Aids
Campos Eliseos– Marylei Castaldelli Verri Deienno;
Prevention and Attendance Center in STD/Aids Lapa
– Elizete Aparecida dos Santos; Pirituba Counseling
Testing Center – Regina Selis Acquesta Dias.
References
1. Janssen R.S., Satten G.A., Stramer S.L., et al. New testing
strategy to detect early HIV-1 infection for use in
incidence estimates and for clinical and prevention
purposes. JAMA 1998;280:42-8.
2. Rawal B.D., Degula A., Lebedeva L., et al. Development
of a new less-sensitive enzyme immunoassay for
detection of early HIV-1 infection. J Acquir Immune Defic
Syndr 2003;33:349-55.
3. Cooper D.A., Imrie A.A., Penny R. Antibody response to
human immunodeficiency virus after primary infection.
J Infect Dis 1987;155:1113-8.
4. Lange J.M., Parry J.V., de Wolf F., et al. Diagnostic value
of specific IgM antibodies in primary HIV infection.
AIDS 1988;2:31-5.
5. McDougal J.S., Kennedy M.S., Nicholson J.K., et al.
Antibody response to human immunodeficiency virus
in homosexual men. Relation of antibody specificity,
titer, and isotype to clinical status, severity of
immunodeficiency, and disease progression. J Clin
Invest 1987;80:316-24.
6. Busch M.P., Satten G.A. Time course of viremia and
antibody seroconversion following human
immunodeficiency virus exposure. Am J Med
1997;102:117-24.
7. Kothe D., Byers R.H., Caudill S.P., et al. Performance
characteristics of a new less sensitive HIV-1 enzyme
immunoassay for use in estimating HIV seroincidence.
J Acquir Immune Defic Syndr 2003;33:625-34.
8. Diaz R.S., Kallas E.G., Castelo A., et al. Use of a new ‘less-
sensitive enzyme immunoassay’ testing strategy to
identify recently infected persons in a Brazilian prison:
estimation of incidence and epidemiological tracing.
AIDS 1999;13:1417-8.
9. Turchi M.D., Diaz R.S., Martelli C.M., et al. Genetic
diversity and HIV-1 incidence estimation among
cocaine users in Sao Paulo, Brazil. J Acquir Immune
Defic Syndr 2002;30:527-32.
10. Schwarcz S.K., Kellogg T.A., McFarland W., et al.
Characterization of sexually transmitted disease clinic
patients with recent human immunodeficiency virus
infection. J Infect Dis 2002;186:1019-22.
11. Gouws E., Williams B.G., Sheppard H.W., et al. High
incidence of HIV-1 in South Africa using a standardized
algorithm for recent HIV seroconversion. J Acquir
Immune Defic Syndr 2002;29:531-5.
Detection of Recent HIV Infection in São Paulo
www.bjid.com.br
406 BJID 2004; 8 (December)
12. Murphy G., Parry J.V., Gupta S.B., et al. Test of HIV
incidence shows continuing HIV transmission in
homosexual/bisexual men in England and Wales.
Commun Dis Public Health 2001;4:33-7.
13. Schechter M., do Lago R.F., de Melo M.F., et al.
Identification of a high-risk heterosexual population for
HIV prevention trials in Rio de Janeiro, Brazil. Projeto
Praco Onze Study Group. J Acquir Immune Defic Syndr
2000;24:175-7.
14. Machado D.M., Delwart E.L., Diaz R.S., et al. Use of the
sensitive/less-sensitive (detuned) EIA strategy for
targeting genetic analysis of HIV-1 to recently infected
blood donors. AIDS 2002;16:113-9.
15. Programa Nacional de DST e Aids. Recomendações para
terapia anti-retroviral em adultos e adolescentes
infectados pelo HIV - 2004. Brasília, DF: Ministério da
Saúde, 2004:61.
16. Programa Nacional de DST e Aids. Boletim epidemiológico
AIDS Dezembro 2003. Vol. 2004: Brazilian Ministry of
Health DST/AIDS Program, 2003.
17. Fiebig E.W., Wright D.J., Rawal B.D., et al. Dynamics of
HIV viremia and antibody seroconversion in plasma
donors: implications for diagnosis and staging of
primary HIV infection. AIDS 2003;17:1871-9.
18. Secretaria Municipal da Saúde do Município de São
Paulo. Boletim Epidemiológico de Aids do Município
de São Paulo. Ano VII, número 7. São Paulo, SP:
Secretaria Municipal da Saúde, 2003.
Detection of Recent HIV Infection in São Paulo
